v3.25.3

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Sep. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 1,275	$ 414
Trade accounts receivable, net	2,828	2,558
Inventories	2,921	2,810
Prepaid income taxes	310	307
Other current assets	701	831
Total current assets	8,035	6,920
Property, plant and equipment, net	3,795	3,294
Goodwill	18,214	17,089
Other intangible assets, net	7,162	6,684
Deferred tax assets	3,669	3,655
Other long-term assets	1,832	1,754
TOTAL ASSETS	42,707	39,395
Current liabilities:
Current debt obligations	483	1,778
Accounts payable	1,002	960
Accrued expenses	2,981	2,773
Other current liabilities	862	887
Total current liabilities	5,328	6,399
Long-term debt	11,117	8,968
Deferred tax liabilities	242	155
Other long-term liabilities	2,390	1,870
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.01 par value - authorized 50,000,000 shares - 0 shares issued as of September 30, 2025 and December 31, 2024	0	0
Common stock, $0.01 par value - authorized 2,000,000,000 shares - 1,745,573,129 shares issued as of September 30, 2025 and 1,737,846,196 shares issued as of December 31, 2024	17	17
Treasury stock, at cost - 263,289,848 shares as of September 30, 2025 and December 31, 2024	(2,251)	(2,251)
Additional paid-in capital	21,419	21,056
Retained earnings	4,899	2,673
Accumulated other comprehensive income (loss), net of tax	(689)	275
Total stockholders’ equity	23,394	21,770
Noncontrolling interests	236	233
Total equity	23,630	22,003
TOTAL LIABILITIES AND EQUITY	$ 42,707	$ 39,395

Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481990/310-10-45-2

BOSTON SCIENTIFIC CORP 10-Q